Multiple myeloma is a heterogeneous disease, which is characterized by the occurrence of specific genomic abnormalities that are both of diagnostic and prognostic relevance. Since the detection of these abnormalities through molecular-genetic techniques is hampered by the overall low percentage of plasma cells present in primary bone marrow aspirates, we assessed the efficacy of these techniques in enriched plasma cell fractions from 61 multiple myeloma patients. Using interphase FISH, genomic abnormalities could be detected in 96% of the enriched samples as compared to 61% in the cultured whole bone marrow samples. We also found that microarray-based genomic profiling of enriched plasma samples facilitates the detection of additional, poss...
This is an open-access paper.Cytogenetic studies in clonal plasma cell disorders have mainly been do...
Blood Cells Mol Dis. 2000 Dec;26(6):634-45. Immunophenotypic aberrations, DNA content, and cell c...
Bone marrow plasma cells (PCs) from 74 patients with newly diagnosed multiple myeloma (MM), 5 with m...
Aim: To evaluate the role of whole genome comparative genomic hybridisation microarray (array-CGH) i...
Multiple myeloma is an incurable malignancy that initiates from a bone marrow resident clonal plasma...
Multiple myeloma (MM) is characterized by marked genomic heterogeneity. Beyond structural rearrangem...
Multiple myeloma (MM) is the most common form of plasma cell dyscrasia, characterized by a marked he...
Introduction: Multiple Myeloma (MM) is characterized by genetic heterogeneity and varied clinical co...
Multiple myeloma (MM) is the most common form of plasma cell dyscrasia, characterized by a marked he...
Multiple myeloma (MM) is the most common form of plasma cell dyscrasia, characterized by a marked he...
marrowplasma cells that accounts for 10% of all hematological malignancies.The broad clinical spectr...
Multiple Myeloma (MM) is the most common form of plasma cell dyscrasia, characterized by a marked he...
marrowplasma cells that accounts for 10% of all hematological malignancies.The broad clinical spectr...
Multiple Myeloma (MM) is the most common form of plasma cell dyscrasia, characterized by a marked he...
Multiple myeloma (MM) is a very heterogeneous disease, characterized by multiple cytogenetic aberrat...
This is an open-access paper.Cytogenetic studies in clonal plasma cell disorders have mainly been do...
Blood Cells Mol Dis. 2000 Dec;26(6):634-45. Immunophenotypic aberrations, DNA content, and cell c...
Bone marrow plasma cells (PCs) from 74 patients with newly diagnosed multiple myeloma (MM), 5 with m...
Aim: To evaluate the role of whole genome comparative genomic hybridisation microarray (array-CGH) i...
Multiple myeloma is an incurable malignancy that initiates from a bone marrow resident clonal plasma...
Multiple myeloma (MM) is characterized by marked genomic heterogeneity. Beyond structural rearrangem...
Multiple myeloma (MM) is the most common form of plasma cell dyscrasia, characterized by a marked he...
Introduction: Multiple Myeloma (MM) is characterized by genetic heterogeneity and varied clinical co...
Multiple myeloma (MM) is the most common form of plasma cell dyscrasia, characterized by a marked he...
Multiple myeloma (MM) is the most common form of plasma cell dyscrasia, characterized by a marked he...
marrowplasma cells that accounts for 10% of all hematological malignancies.The broad clinical spectr...
Multiple Myeloma (MM) is the most common form of plasma cell dyscrasia, characterized by a marked he...
marrowplasma cells that accounts for 10% of all hematological malignancies.The broad clinical spectr...
Multiple Myeloma (MM) is the most common form of plasma cell dyscrasia, characterized by a marked he...
Multiple myeloma (MM) is a very heterogeneous disease, characterized by multiple cytogenetic aberrat...
This is an open-access paper.Cytogenetic studies in clonal plasma cell disorders have mainly been do...
Blood Cells Mol Dis. 2000 Dec;26(6):634-45. Immunophenotypic aberrations, DNA content, and cell c...
Bone marrow plasma cells (PCs) from 74 patients with newly diagnosed multiple myeloma (MM), 5 with m...